Home » Topics » BioWorld Science

BioWorld Science
RSS

Response rate shows potential of ficlatuzumab with chemotherapy in treating AML

Aug. 9, 2021

AstraZeneca starts phase II SOLANO study of AZD-8233

Aug. 9, 2021

Initiation of phase I/II clinical trial of AK-117 in patients with AML

Aug. 9, 2021

Atridia initiates phase I study of SHR-1905

Aug. 9, 2021

Signal peptide peptidase-like 2B has a pathogenic role in Alzheimer's disease

Aug. 9, 2021

Enrollment ongoing in phase II study of USB-002 for respiratory distress due to COVID-19

Aug. 9, 2021

Antengene and MindRank AI collaborate to advance difficult-to-drug molecular targets

Aug. 9, 2021

Phase II study of ASC-40 for the treatment of acne vulgaris approved in China

Aug. 9, 2021

Proteins found to promote neuroinflammation in MS

Aug. 9, 2021

Bentrio shows prophylactic and therapeutic effects against influenza A

Aug. 9, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...